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Abstract
Background: Mitochondrial ATP synthase is expressed as a plasma membrane receptor for apolipoprotein A-I (apoA-I), the
major protein component in High Density Lipoproteins (HDL). On hepatocytes, apoA-I binds to cell surface ATP synthase
(namely ecto-F1-ATPase) and stimulates its ATPase activity, generating extracellular ADP. This production of extracellular
ADP activates a P2Y13-mediated HDL endocytosis pathway. Conversely, exogenous IF1, classically known as a natural
mitochondrial specific inhibitor of F1-ATPase activity, inhibits ecto-F1-ATPase activity and decreases HDL endocytosis by
both human hepatocytes and perfused rat liver.
Methodology/Principal Findings: Since recent reports also described the presence of IF1 at the plasma membrane of
different cell types, we investigated whether IF1 is present in the systemic circulation in humans. We first unambiguously
detected IF1 in human serum by immunoprecipitation and mass spectrometry. We then set up a competitive ELISA assay in
order to quantify its level in human serum. Analyses of IF1 levels in 100 normolipemic male subjects evidenced a normal
distribution, with a median value of 0.49 mg/mL and a 95% confidence interval of 0.22–0.82 mg/mL. Correlations between
IF1 levels and serum lipid levels demonstrated that serum IF1 levels are positively correlated with HDL-cholesterol and
negatively with triglycerides (TG).
Conclusions/Significance: Altogether, these data support the view that, in humans, circulating IF1 might affect HDL levels
by inhibiting hepatic HDL uptake and also impact TG metabolism.
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Introduction
The role of High Density Lipoproteins (HDL) in protecting
against atherosclerosis is now well established but the mechanism
supporting this is still debated. The original proposal, supported by
a wide range of evidences, attributes this atheroprotective effect of
HDL particles to their metabolic role in ‘‘reverse cholesterol
transport’ (RCT), a process which carries cholesterol from
peripheral tissues back to the liver for further catabolism. In
addition, HDL have a direct atheroprotective effect on the
vascular wall through anti-inflammatory, antioxidant and anti-
thrombotic actions involving inter alia the production of nitric oxide
(NO). Hepatic uptake of HDL particles is a key step in RCT [1].
Two distinct mechanisms of HDL-cholesterol uptake have been
described in hepatocytes: i) selective cholesterol uptake, a
mechanism through which cholesterol (free or esterified) is taken
up while the protein components of the HDL particle are not; ii)
HDL endocytosis resulting in the uptake and degradation of HDL
holoparticle [2]. In contrast to the well-established role of the
Scavenger receptor class B member I (SR-BI) in selective
cholesterol uptake by hepatocytes [3], a distinct pathway seems
to be involved in HDL holoparticle endocytosis [4]. A likely
candidate mediating HDL holoparticle endocytosis is the cell
surface complex related to mitochondrial ATP synthase (namely
ecto-F1-ATPase) [5]. Apolipoprotein A-I (apoA-I) binding to ecto-
F1-ATPase stimulates extracellular ATP hydrolysis to ADP and
the latter specially activates the nucleotide receptor P2Y13
resulting in HDL holoparticle endocytosis [6,7]. We and others
have described that P2Y13-knock out mice displayed altered HDL
hepatic catabolism and impaired RCT [8,9], strongly suggesting
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e23949
14that this ecto-F1-ATPase/P2Y13-mediated HDL endocytosis
pathway might play an important role in HDL metabolism in vivo.
Thus, regulation of ecto-F1-ATPase activity, which generates
extracellular ADP, might directly impact on P2Y13 activation and
subsequent hepatic HDL uptake. In mitochondria, the endoge-
nous inhibitory protein IF1 regulates the ATPase activity of FOF1-
ATP synthase [10]. IF1 is a basic amphiphilic mitochondrial
protein of 81 amino acids (NCBI Reference Sequence:
NP_057395.1 NM_016311.4) with a significant degree of
homology in various species [11]. Data from high-resolution
crystallography have shown that IF1 binds through its N-terminal
region at the interface between aDP- and bDP-subunits of the F1
catalytic sector of mitochondrial ATP synthase, thereby blocking
rotary catalysis [12].
Therefore, IF1 regulates mitochondrial energetic functions
under both physiological and pathological conditions, such as
ischemic injury, by maintaining mitochondrial ATP levels when
ATP synthase switches from ATP synthesis to ATP hydrolysis
[13,14]. We and others have also reported that exogenous IF1
could specifically bind to ecto-F1-ATPase on hepatocytes and
endothelial cells and reduce its hydrolytic activity [6,15,16].
Interestingly, exogenous IF1 was able to reduce by about 50%
HDL uptake by perfused rat liver [6], suggesting that the
inhibitory effect of IF1 on ecto-F1-ATPase activity might impact
on HDL metabolism. More recently, endogenous IF1 has been
identified on the surface of both endothelial cells and hepatocytes
[16,17,18,19], suggesting that endogenous IF1 might also be a
potent regulator of HDL metabolism.
In this study, we describe for the first time the presence of
endogenous IF1 in human serum and further analyze the
correlation between IF1 and serum lipid levels in 100 normoli-
pemic subjects.
Results
Identification of IF1 in human serum
A polyclonal antibody was raised against human recombinant
IF1 (rIF1) and purified as described in the Materials and Methods
section. Interaction of this anti-IF1 antibody with rIF1 was
controlled by Surface Plasmon Resonance (SPR) analysis (Fig. 1A).
In these conditions, rIF1 specifically bound to anti-IF1 immobi-
lized onto SPR chips (KD=6.1 nM). To further evaluate the
specificity of anti-IF1, we performed immunofluorescence exper-
iments in HeLa cells. Immunolabeling with anti-IF1 antibody
showed a characteristic mitochondrial pattern (Fig. 1B). This was
further confirmed by colocalization of IF1 staining with mito-
chondrial markers such as MitoTracker (Fig. 1B) or the alpha
subunit of ATP synthase (Fig. 1C). This staining is completely lost
when cells were treated with siRNA against IF1 (Fig. 1D),
highlighting the specificity of anti-IF1 antibody. Altogether, these
data demonstrate the specificity of the anti-IF1 antibody toward
recombinant and endogenous IF1 protein.
This antibody was then used to immunopurify IF1 from a pool
of serum enriched in low-abundance proteins and from HepG2
cell lysate. Proteins from the immunopurified fractions were then
separated on a polyacrylamide gel and immunoblotted with anti-
IF1 antibody. As compared to immunoprecipitation performed
using pre-immune IgG, a specific signal for IF1 was detected in
anti-IF1 immunopurified fractions from both human serum and
HepG2 cell lysate (Fig. 2A). Interestingly, in these conditions, IF1
from serum and hepatocytes appeared as a double band, at the
size of a dimer whereas under the same conditions, purified rIF1 is
immunoprecipitated both as a monomer and a dimer. However,
upon longer exposure time, a faint specific band at the size of the
monomer can also be detected in immunoprecipitated samples
from both serum and HepG2 cell lysate (data not shown). This
result suggested that IF1 was present in human serum and mostly
found as a dimeric form, like in hepatocytes.
In order to confirm the presence of IF1 in human serum, a
targeted proteomics method has been implemented: the detection
of IF1 by Multiple Reaction Monitoring (MRM, also called
Selected Reaction Monitoring, SRM) mass spectrometry has been
optimized using the rIF1. Four peptides (EQLAALK, EQ-
LAALKK, LQKEIER, HHEEEIVHHK) were monitored and
the corresponding MS/MS sequences were acquired. The same
method has then been used on human serum pool sample
previously enriched for minor proteins using ProteoMiner
TM
protocol. The comparable MRM traces and MS/MS fragmenta-
tion spectra for all four peptides in rIF1 and serum sample
demonstrate the presence of IF1 in human serum. This was
confirmed by a protein database search with serum sample spectra
using Mascot software. The results obtained for one of these
peptides are shown in figure 2B. Altogether, these data
unambiguously demonstrated the presence of IF1 in human
serum.
Quantification of IF1 serum levels in the general
population and correlation with serum lipid parameters
On the basis of the use of anti-IF1 antibody, a competitive
ELISA was developed as described in Materials and Methods
section to quantify IF1 in human serum. Figure 3 displays a typical
standard curve used for the ELISA, ranging from 0 to 2.5 mg IF1/
mL. Fifty percent displacement was obtained at a concentration of
0.4 mg/mL. Repeatability (within the same day) and reproduc-
ibility (10 measurements over a 6-month period) gave variation
coefficients of 6–7%. An average recovery of 96.8% was measured
in dilution experiments. Resistance to freezing and thawing was
assessed in different occasions with a 95%–103% agreement
between measurements. With regard to possible correlations of IF1
with HDL markers, competition experiments with purified
apolipoproteins A-I and A-II indicated no cross reactivity in this
immunoassay (data not shown).
IF1 concentrations were measured among 100 healthy normo-
lipemic male subjects, randomly selected from a population study.
Among others, mean parameters (means 6 SD) for this sub-
population were: age, 59.168,8 y; body mass index (BMI),
26.863.5 kg/m
2; systolic blood pressure, 136.9616.0 mm Hg,
glycaemia, 5.561.1 mmol/L; cholesterol, 2.360.37 g/L and
triglycerides, 1.2360.75 g/L. Regarding all investigated charac-
teristics, this sub-population did not differ from the whole
population study. IF1 concentrations displayed a normal distribu-
tion with an average value of 0.5260.16 mg/mL, a median at
0.49 mg/mL and a 95% confidence interval of 0.22–0.82 mg/mL.
Serum lipid levels were compared from both sides of IF1 median.
In subjects with elevated IF1, HDL-cholesterol was significantly
higher and triglycerides (TG) or VLDL-cholesterol were lower,
while there was no difference regarding total or LDL-cholesterol
(Table 1). Moreover, correlations between IF1 serum levels and
HDL-cholesterol and TG are displayed with all individual data
points in Figure 4A and 4B respectively. Correlation analysis
demonstrated that IF1 serum level was positively associated with
HDL-cholesterol (r=0.259, p=0.009) and negatively associated
with TG (r=20,261, p=0.009). No difference was recorded
according to IF1 distribution in other investigated parameters,
such as glucose level, cigarette smoking, alcohol consumption or
physical activity (data not shown). These data support the view
that IF1 might have an impact on the metabolism of both HDL
and TG-rich lipoproteins.
IF1 in the Systemic Circulation
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e23949Figure 1. Characterization of polyclonal anti-IF1 antibody. (A) Sensorgrams are representative of specific interactions (differential response)
while nonspecific binding (with no protein immobilized) was deduced. rIF1 was injected at a concentration ranging from 12.5 to 400 nM. Results are
expressed as resonance units (RU) as a function of time in seconds. The apparent kinetic constants of the interaction were ka=3.87e
5 M
21 s
21,
kd=2.37e
23 s
21, and KD=6.12e
29 M. (B) HeLa cells were incubated or not with Mitotracker for 30 min at 37uC. Cells were then fixed and processed
for immunofluorescence using anti-IF1 antibody. (C) HeLa cells were fixed and processed for immunofluorescence using both anti-IF1 and anti-alpha
subunit of ATP synthase (alpha) antibodies. In (B) and (C), the merged images demonstrate perfect overlap between IF1 and both Mitotraker and
alpha chain of mitochondrial ATP synthase. (D) HeLa cells were treated with siRNAs against IF1, fixed and then processed for immunofluorescence
using anti-IF1 antibody and DAPI for nuclear stain. (B–D) Scale bar indicates 10 mm.
doi:10.1371/journal.pone.0023949.g001
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e23949Figure 2. Identification of IF1 in human serum. (A) Recombinant IF1 (rIF1) or low-abundance protein-enriched serum or HepG2 cell lysates were
subjected to immunoprecipitation with pre-immune antibodies (PI) or anti-IF1 antibodies (Ab). Analysis was performed by Western blotting using
antibodies against IF1. On the left panel, 1 mg rIF1 was loaded as a control of molecular weight. Arrow points at 2 bands immunoprecipitated with
specific anti-IF1 antibody. (B) (a) Multiple Reaction Monitoring of EQLAALKK peptide of rIF1 (high panel), blank run before the serum sample (middle
panel) and serum sample (low panel). Note the scale difference between rIF1, the serum sample and blank run. Three parent/fragment transitions are
monitored for each peptide (represented in three different colors). (b) Manually annotated MS/MS fragmentation spectra of EQLAALKK peptide of
human IF1 from serum sample.
doi:10.1371/journal.pone.0023949.g002
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For the first time, we unambiguously demonstrated the presence
of IF1 in human serum using a recently developed targeted
proteomics approach allowing the identification of low-abundance
proteins with high sensitivity and specificity [23]. This is in line
with recent studies reporting ectopic localisation of endogenous
IF1 at the cell surface of different cell types including endothelial
cells [17] and hepatocytes [16,18,19]. Thus, IF1 is not strictly
confined within the mitochondria but is ectopically expressed at
the cell surface or circulating in human serum. Interestingly,
previous studies reported that IF1 can switch between two
different states: an active dimeric form and an inactive tetrameric
form, depending on the pH [24,25]. In our conditions, after SDS-
PAGE and western blotting, we indeed detected recombinant IF1
both as a monomer and a dimer, suggesting that dimerization of
IF1 was resistant to denaturing conditions. Identification of IF1 in
human serum by mass spectrometry analysis was performed from
digested fragments corresponding to the size of the monomeric
IF1. Analysis of serum sample at the size of the dimer has not been
conducted because serum proteins detected by colloidal blue
staining were much more abundant at the size of the dimer, which
would make IF1 peptides more difficult to detect. However, in
immunoprecipitation experiments, we mainly detected IF1 in the
serum at the size of the dimer, even if monomer can also be
detected upon longer exposure times. This suggests that both
monomeric and dimeric forms of IF1 are present in serum but IF1
seems to be mostly found as the active dimeric form, like in HepG2
cells. The formation of the IF1 dimer might be dependent on
various parameters, such as pH conditions or post-translational
modifications. The physiological pH of our samples for western
blotting in all conditions is consistent with the presence of the
dimers [25]. In addition, post-translational modifications could
also favour or stabilize the formation of the dimers in serum.
Furthermore, since the dimeric form of IF1 appears as a double
band, we can hypothesize that IF1 is associated with other serum
proteins. It is also conceivable that the double band reflects some
post-translational modifications or alternative splicing of IF1.
Indeed, alternative splicing occurs at IF1 gene locus, leading to
distinct transcript variants. In human, three different isoforms
have been identified. IF1 variant (NCBI Reference Sequence:
NP_057395.1) encodes the longest isoform, while IF1 variant 2
(NCBI Reference Sequence: NP_835497.1) and variant 3 (NCBI
Reference Sequence: NP_835498.1) have a shorter and distinct C-
terminus compared to isoform 1. Mass spectrometry led to the
identification of four peptides that only overlap with the C-
terminus part of IF1 variant 1. However, one might speculate that
different IF1 variants are present in human serum since our anti-
IF1 antibody recognizes all these variants (data not shown).
Therefore, further investigations are needed to better characterize
the molecular components of dimeric IF1.
In this study, the first measurements of serum IF1 concentra-
tions have been performed among normal healthy male adults,
showing a normal distribution (95% confidence interval: 0.22–
0.82 mg/mL). Moreover, HDL-cholesterol was significantly differ-
ent according to IF1 distribution, a positive correlation being
observed between both parameters (r=0.259, p=0.009). Inter-
estingly, no relationship was found between IF1 levels and various
environmental parameters known to affect HDL concentrations,
such as cigarette smoking, alcohol consumption or physical
activity. This suggests that IF1 could have an impact on HDL
levels independently on those environmental factors. As reminded
above, experiments in cultured hepatocytes and in perfused rat
livers have demonstrated that exogenous IF1 impairs the hepatic
uptake of HDL particles through the ecto-F1-ATPase/P2Y13
pathway [6]. In line with these observations, Giorgio et al. recently
reported that, upon bile-duct ligation in rat, ecto-F1-ATPase
activity was downregulated due to an increased expression level of
endogenous IF1 at the cell surface [19]. Altogether these data
suggest that IF1 might control hepatic HDL-cholesterol catabo-
Figure 3. Typical standard curve used for IF1 quantification.
Competitive ELISA was performed using rIF1-coated plates (0.5 mg/mL)
and biotinylated anti-IF1 polyclonal antibody pre-incubated with
different dilutions of rIF1 (0 to 2.5 mg/mL). The colorimetric signal (OD
450 nm–OD 570 nm) is expressed as a part of the maximum signal
obtained without rIF1, B/B0. The standard curve shows that fifty percent
displacement of binding was obtained at a concentration of 0.4 mg/mL
rIF1.
doi:10.1371/journal.pone.0023949.g003
Table 1. Correlations between IF1 levels and lipid parameters in serum.
Below IF1 median (n=50) Above IF1 median (n=50) p
Total Cholesterol (g/L) 2.30 (0.37) 2.31 (0.35) 0.87 (NS)
HDL-C (g/L) 0.53 (0.12) 0.58 (0.11) 0.04 *
LDL-C (g/L) 1.48 (0.34) 1.51 (0.29) 0.59 (NS)
VLDL-C (g/L) 0.29 (0.02) 0.22 (0.01) 0.01 *
Triglycerides (g/L) 1.45 (0.82) 1.11 (0.42) 0.03# *
Serum lipid levels were compared from both sides of IF1 median (IF1 median=0.49 mg/mL). Values are expressed as means and (SD); n=100 normolipemic male
subjects from the study population.
*Indicates significant difference (p,0.05; # after log transformation).
doi:10.1371/journal.pone.0023949.t001
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humans leading to increased HDL-cholesterol levels. A compara-
ble situation is encountered with hepatic lipase variants. Hepatic
lipase, located in sinusoid capillaries, acts on HDL particles and
stimulates their subsequent liver uptake [26]. Common genetic
variants within the promoter result in a decreased in vivo hepatic
lipase activity, repeatedly associated with elevated HDL levels
[27]. Whether the 10% variation of HDL-cholesterol observed
from both sides of IF1 median is relevant regarding cardiovascular
risk protection needs further investigations. Only one other
parameter, TG level and correlatively VLDL-cholesterol, was
found different according to IF1 concentrations. So far, we have
no evidence of a particular impact of IF1 on TG metabolism.
However, components of the ATP synthase complex have been
described at the surface of adipocytes and might participate to the
control of lipid storage [28]. Also, a direct impact of IF1 on the
metabolism of TG-rich lipoproteins cannot be excluded. Serum
TG and HDL-cholesterol are inversely interrelated. Thus, further
determinations of serum IF1 in larger populations and in various
pathophysiological contexts are required, in order to assess
whether or not IF1 can be considered as a new, independent
determinant of HDL levels.
Materials and Methods
Study Population
The study population was approved by the local Ethics
Committee of the hospital of Toulouse (CHU Toulouse/
INSERM) and written informed consent was obtained from all
participants involved in the study. Biological collection was
constituted according to the principles expressed in the Declara-
tion of Helsinki and registered under number DC-2008-403 at the
Ministry of Research and at the Regional Health Agency.
Subjects were randomly selected from controls of a large case-
control study carried out in the Toulouse area (France), by the
Cardiovascular Epidemiology team of our University (Dr J.B.
Ruidavets). They were all participants of a study on genetic,
biological and environmental determinants of coronary artery
disease (referenced as Genes study, [20]). In the frame of this
study, 800 control male healthy subjects, aged 45–75, were
randomly selected from the general population using electoral
rolls. Subjects had an extensive evaluation of cardiovascular risk
factors and clinical investigation included anthropometric vari-
ables, blood pressure measurements, measured twice at rest, and
assessment of various metabolic parameters. Of this control
population, 100 subjects were randomly drawn for serum IF1
measurements.
Constructs, RNA interference and transfection
The sequence encoding the mature peptide of human IF1 (NCBI
Reference Sequence: NM_016311.4), without the sequence of the
mitochondrial targeting signal (MTS), was amplified by PCR from
HeLa cell cDNA. The amplified fragment was then introduced at
BamHI/HindIII restriction sites into VariFlex Expression vector
pBEn-SBP-SET1-Qa (Stratagene) containing the Streptavidin
Binding Peptide coding sequence (SBP tag). The resulting
expression plasmid was verified by DNA sequencing and known
as pBEn-SBP-IF1. In RNA interference (RNAi) experiments, cells
were transfected twice at a 24 h interval using LipofectamineTM
RNAiMAX transfection Reagent (Invitrogen) with 21-nucleotide
RNA duplexes (siRNA Hs ATPIF1 6 from Qiagen), replated 4 h
after the second transfection, and analyzed 36 h later.
Recombinant protein
Recombinant human IF1 (rIF1) was produced in E. coli BL21
(DE3) strain. Briefly, the bacterial pellet was resuspended in lysis
buffer (0.5 M NaCl, 0.7 M sucrose, 1 mM EDTA, 1% Triton X-
100, 5 mM b-mercaptoethanol, Roche protease inhibitor cocktail)
and then sonicated. The soluble proteins including rIF1 were
diluted in binding buffer (50 mM ammonium carbonate, 0.5 M
NaCl, pH 10.0), filtered through a 0.22 mm filter and then applied
at 1 mL/min to a HiTrap
TM Streptavidin HP 1 mL column (GE
Healthcare). After washes, rIF1 was eluted in 6 M guanidine
elution buffer. Pooled fractions containing rIF1 protein fused with
SBP tag were dialyzed against thrombin-cleavage buffer (20 mM
Tris-HCl pH 8.4, 150 mM NaCl, 2.5 mM CaCl2) and thrombin
(10 U/mg protein) was added overnight at room temperature in
order to cleave the SPB tag. The sample was then loaded onto
HiTrap
TM Streptavidin HP 1 mL column and pure IF1 was found
in the flow-through fraction. rIF1 was .95% pure as determined
by SDS-PAGE (data not shown).
IF1 antiserum preparation
A polyclonal antibody was raised in New Zealand White rabbits
against recombinant human IF1 (P.A.R.I.S, Compie `gne, France).
Total serum IgG were purified from serum by affinity chroma-
tography using protein A Sepharose CL-4B columns (GE
healthcare), according to manufacturer’s instructions. Purity of
IgG fractions was assessed by SDS-PAGE. Specific IgG against
IF1 were purified from total serum IgG by affinity chromatogra-
phy using IF1 column.
SPR (Biacore) Analysis
Purified anti-IF1 antibody was immobilized by amine linkage
on CM5 chips (Biacore AB) after NHS-EDC activation. Binding
Figure 4. Correlation between IF1 levels and HDL-C (panel A) and TG (panel B). All individual data of measurements in 100 normolipemic
male subjects are represented. Regression coefficients (r) and statistical significance (p) are given.
doi:10.1371/journal.pone.0023949.g004
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tions of rIF1 were injected at a flow rate of 20 mL/min, exposed to
the surface for 175 s (association phase), followed by a 200 s flow
running during which dissociation occurred. Between injections, in
order to recover the prebinding baseline, the sensorchip surface
was regenerated by a 5 mL injection of 0.01% SDS (15 s of contact
time). The apparent Kd value was calculated with the CLAMP
software [21].
Immunofluorescence
HeLa cells cultured on coverslips were incubated or not with
Mitotracker (Invitrogen) for 30 min at 37uC. Then, cells were
fixed with 4% paraformaldehyde and permeabilized with 0.1%
Triton X-100 for 60 min. After saturation of unspecific sites with
PBS containing 10% foetal calf serum, cells were first incubated
with the primary antibody (monoclonal anti-alpha ATP synthase
from Invitrogen; polyclonal anti-IF1 antibody), then with fluores-
cently labeled secondary antibodies from Jackson Immunore-
search Laboratories (West Grove, PA). Pictures were captured
using a Zeiss LSM 710 confocal microscope equipped with a 636
Plan-Apochromat objective.
Immunoprecipitation
100 mL of serum from 10 individuals selected from the study
population were pooled together. This serum pool was then pre-
fractioned using the ProteoMiner
TM kit (Bio-Rad Laboratories)
according to the manufacturer’s protocol. Immunoprecipitation of
IF1 from human serum was performed using Pierce H Crosslink
Immunoprecipitation Kit (ThermoScientific) according to manu-
facturer’s instructions. Briefly, 10 mg of pre-immune antibodies or
anti-IF1 antibodies were covalently crosslinked onto protein A/G
resin and then incubated overnight with 2 mg of recombinant IF1
(rIF1) or 500 mg of proteins either from serum or from HepG2 cell,
after cell lysis in 150 mM NaCl, 1% Triton X-100, 20 mM Tris
pH 7.6, protease inhibitor cocktail (Roche). After washes, the
bound proteins were eluted in 0.2 M glycine pH 2.8 and 56
Laemmli sample buffer (200 mM Tris-HCl pH 6.8, 10% SDS,
50% glycerol, 125 mM DTT, 0.05% bromophenol blue) was
added. Protein samples were then boiled for 5 min, loaded on
15% SDS-PAGE and transferred to nitrocellulose membrane,
which was incubated at room temperature for 1 h in 5% non-fat
dry milk in TBS (50 mM Tris, 150 mM NaCl) containing 0.05%
Tween 20 (TBST). The membrane was incubated overnight at
4uC in TBST containing 1% non-fat dry milk and 1% BSA with
our in-house developed anti-IF1 antibody at 1 mg/mL. The
membrane was washed three times in TBST and incubated with
anti-rabbit IgG-Horse Radish Peroxidase-conjugated antibody (1/
4000) then rinsed in TBST and revealed for chemiluminescence
(Sigma).
Targeted analysis by Multiple Reaction Monitoring
500 mg of pre-fractioned serum proteins were diluted in
Laemmli sample buffer as well as 5 mg of rIF1. Cysteine S-S
bridges were reduced and alkylated by iodoacetamide and the
samples were then loaded onto a 15% polyacrylamide gel. After
Coomassie Blue staining, one major visible band corresponding to
rIF1 monomer was cut. In parallel, a slice was cut at the same
molecular weight size than rIF1 in serum sample lane. The gel
slices were washed with 100 mM ammonium bicarbonate and
then with 100 mM ammonium bicarbonate, acetonitrile (1:1).
Proteins were digested in gel by incubation with 0.6 mg of modified
sequencing grade trypsin (Promega) in 50 mM ammonium
bicarbonate at 37uC overnight. The resulting peptides were
extracted by several incubations with acetonitrile and 10% formic
acid, dried in a SpeedVac, and finally resuspended in 5%
acetonitrile, 0.05% trifluoroacetic acid. The peptide mixture from
rIF1 was used for optimisation of human IF1 detection by
nanoLC/MS in Multiple Reaction Monitoring (MRM) mode
using an Ultimate 3000 system (Dionex, Amsterdam, The
Netherlands) coupled to a 5500 QTrap mass spectrometer (AB
Sciex, Foster City, CA, USA). 1 pmol of rIF1 was loaded on a C18
precolumn (300-mm inner diameter65 mm, Dionex, Amsterdam,
The Netherlands) at 20 mL/min in 2% acetonitrile, 0.05%
trifluoroacetic acid. After desalting, the precolumn was switched
on-line with the analytical column (75 mm inner diameter615 cm
silica capillary tubing packed with Reprosil-Pur C18-AQ 3 mm
phase, Dr. Maisch, GmbH, Germany) equilibrated in 100%
solvent A (5% acetonitrile, 0.2% formic acid). Peptides were eluted
using a 0–50% gradient of solvent B (80% acetonitrile, 0.2%
formic acid) during 25 min at 300 nL/min flow rate. The 5500
QTrap was operated in MRM mode with the Analyst software
(version 1.5.1, AB Sciex, Foster City, CA, USA). Four peptides of
human IF1 giving the most intense signals were monitored in
MRM with quadrupole Q1 and Q3 set to Unit resolution, optimal
collision energies and declustering potentials were determined for
three parent/fragment transitions of each peptide. During the run,
full scan MS/MS acquisitions (EPI, Enhanced Product Ion) were
also triggered when MRM signal exceeded 200 counts, with a
mass tolerance of 250 mDa, the Linear Ion Trap (LIT) was set at
150 ms fixed fill time. A third of the peptide extract from serum
sample was then loaded on the system in the same way than rIF1
and the analysis by the 5500 QTrap was performed in the same
mode (MRM+EPI) with the optimized transition list. A blank run
in the same conditions was performed before analyzing the serum
sample in order to ensure the non-contamination of the nanoLC
system by rIF1. The Mascot Daemon software (version 2.3.2,
Matrix Science, London, UK) was used to perform database
searches. To automatically extract peak lists from Analyst wiff files,
the Mascot.dll macro (version 1.6b27) provided with Analyst was
used and set for no grouping of MS/MS scans. Data were
searched against Homo sapiens entries in the Uniprot protein
database (September 2010 version – 96635 sequences). Carbami-
domethylation of cysteines was set as a fixed modification and
oxidation of methionines and deamidation of asparagines and
glutamines were set as variable modifications for Mascot searches.
Specificity of trypsin digestion was set for cleavage after lysine or
arginine except before proline, and two missed trypsin cleavage
sites were allowed. The mass tolerances in MS and MS/MS were
set to 0.6 Da, and the instrument setting was specified as ‘‘ESI-
QUAD’’.
Competitive ELISA
A competitive ELISA was devised in order to quantify IF1 in
human sera. The wells of 96-well Polysorb ELISA plates (NUNC,
Roskilde, Denmark) were coated with 50 ng of rIF1 in bicarbonate
buffer (0.1 M, pH 9.6). Serum samples were thawed at room
temperature and 50 mL of each patient serum, or rIF1 standard (0;
0.025; 0.050; 0.075; 0.1; 0.3; 1 and 2.5 mg/mL), were incubated
with biotinylated anti-IF1 polyclonal antibody (dilution: 1/1000 in
PBS; 0.05% Tween-20; 1% BSA) overnight at 4uC. The plates
were washed and then incubated with blocking buffer (PBS buffer
pH 7.4, 3% BSA) for 1 hour at room temperature. After washing,
the sample/antibody mixtures were added and incubated for
4 hours at room temperature. The plates were washed again and
incubated with streptavidin-HRP (dilution: 1/5000 in PBS
pH 7.4; 0.05%Tween-20; 1% BSA) (Invitrogen, Cergy Pontoise,
France) for 1 hour at room temperature. After washing, plates
were incubated with horseradish peroxidase (HRP) substrate TMB
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HCl 1N, and the plates were then read at 450 nm in a microplate
reader (Varioscan Flash, Thermo electron corporation). The
570 nm optic density (background) was subtracted. Sample
concentrations were determined using the standard curve (fit type:
four parameter logistic).
Serum lipid and glucose measurements
Blood was collected after an overnight fast. Serum total
cholesterol, HDL-cholesterol (HDL-C), triglycerides (TG) and
glucose were assayed with enzymatic reagents on an automated
analyzer (Hitachi 912, Roche Diagnostics, Meylan, France). LDL-
cholesterol (LDL-C) was calculated using the Friedewald formula,
with VLDL-C (g/L)=TG (g/L)/5 as long as TG concentration is
below 4 g/L [22].
Statistical analysis
All results are presented as means and SD (Standard Deviation).
Comparison between groups was made using two-tailed unpaired
Student’s t tests. A logarithmic transformation was done for
triglycerides, because of skewed distribution. Pearson and
Spearman coefficients were calculated to study correlations
between IF1 serum level and HDL-C and TG serum levels
respectively. Outcomes of p,0.05 were considered as statistically
significant. Analyses were performed using GraphPad Prism 5
software (GraphPad Software, La Jolla, CA, U.S.A.).
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